Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Hematol Oncol Clin North Am. 2009 Apr;23(2):215-31. doi: 10.1016/j.hoc.2009.01.003.

    Dyskeratosis congenita.

    Source

    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20852, USA. savagesh@mail.nih.gov

    Abstract

    Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome characterized clinically by the triad of abnormal nails, reticular skin pigmentation, and oral leukoplakia, and is associated with high risk of developing aplastic anemia, myelodysplastic syndrome, leukemia, and solid tumors. Patients have very short germline telomeres, and approximately half have mutations in one of six genes encoding proteins that maintain telomere function. Accurate diagnosis of DC is critical to ensure proper clinical management, because patients who have DC and bone marrow failure do not respond to immunosuppressive therapy and may have increased morbidity and mortality associated with hematopoietic stem cell transplantation.

    PMID:
    19327580
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2702847
    Free PMC Article

    Images from this publication.See all images (3)Free text

    Figure 1
    Figure 2
    Figure 3

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      Recent activity

      • Dyskeratosis congenita.
        Dyskeratosis congenita.
        Hematol Oncol Clin North Am. 2009 Apr ;23(2):215-31. doi: 10.1016/j.hoc.2009.01.003.
        PubMed

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk